Literature DB >> 19955365

Posttranslational modification of ataxin-7 at lysine 257 prevents autophagy-mediated turnover of an N-terminal caspase-7 cleavage fragment.

Shona Mookerjee1, Theodora Papanikolaou, Stephan J Guyenet, Vanitha Sampath, Amy Lin, Cathy Vitelli, Francesco DeGiacomo, Bryce L Sopher, Sylvia F Chen, Albert R La Spada, Lisa M Ellerby.   

Abstract

Polyglutamine (polyQ) expansion within the ataxin-7 protein, a member of the STAGA [SPT3-TAF(II)31-GCN5L acetylase] and TFTC (GCN5 and TRRAP) chromatin remodeling complexes, causes the neurodegenerative disease spinocerebellar ataxia type 7 (SCA7). Proteolytic processing of ataxin-7 by caspase-7 generates N-terminal toxic polyQ-containing fragments that accumulate with disease progression and play an important role in SCA7 pathogenesis. To elucidate the basis for the toxicity of these fragments, we evaluated which posttranslational modifications of the N-terminal fragment of ataxin-7 modulate turnover and toxicity. Here, we show that mutating lysine 257 (K257), an amino acid adjacent to the caspase-7 cleavage site of ataxin-7 regulates turnover of the truncation product in a repeat-dependent manner. Modification of ataxin-7 K257 by acetylation promotes accumulation of the fragment, while unmodified ataxin-7 is degraded. The degradation of the caspase-7 cleavage product is mediated by macroautophagy in cell culture and primary neuron models of SCA7. Consistent with this, the fragment colocalizes with autophagic vesicle markers, and enhanced fragment accumulation increases in these lysosomal structures. We suggest that the levels of fragment accumulation within the cell is a key event in SCA7 neurodegeneration, and enhancing clearance of polyQ-containing fragments may be an effective target to reduce neurotoxicity in SCA7.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19955365      PMCID: PMC2907146          DOI: 10.1523/JNEUROSCI.4720-09.2009

Source DB:  PubMed          Journal:  J Neurosci        ISSN: 0270-6474            Impact factor:   6.167


  49 in total

1.  Impairment of the ubiquitin-proteasome system by protein aggregation.

Authors:  N F Bence; R M Sampat; R R Kopito
Journal:  Science       Date:  2001-05-25       Impact factor: 47.728

2.  SUMO-1 co-localized with mutant atrophin-1 with expanded polyglutamines accelerates intranuclear aggregation and cell death.

Authors:  Tomoya Terashima; Hiromichi Kawai; Masashi Fujitani; Kengo Maeda; Hitoshi Yasuda
Journal:  Neuroreport       Date:  2002-12-03       Impact factor: 1.837

3.  Association of ataxin-7 with the proteasome subunit S4 of the 19S regulatory complex.

Authors:  A Matilla; C Gorbea; D D Einum; J Townsend; A Michalik; C van Broeckhoven; C C Jensen; K J Murphy; L J Ptácek; Y H Fu
Journal:  Hum Mol Genet       Date:  2001-11-15       Impact factor: 6.150

4.  Similarities between spinocerebellar ataxia type 7 (SCA7) cell models and human brain: proteins recruited in inclusions and activation of caspase-3.

Authors:  C Zander; J Takahashi; K H El Hachimi; H Fujigasaki; V Albanese; A S Lebre; G Stevanin; C Duyckaerts; A Brice
Journal:  Hum Mol Genet       Date:  2001-10-15       Impact factor: 6.150

5.  Polyglutamine-expanded ataxin-7 antagonizes CRX function and induces cone-rod dystrophy in a mouse model of SCA7.

Authors:  A R La Spada; Y H Fu; B L Sopher; R T Libby; X Wang; L Y Li; D D Einum; J Huang; D E Possin; A C Smith; R A Martinez; K L Koszdin; P M Treuting; C B Ware; J B Hurley; L J Ptácek; S Chen
Journal:  Neuron       Date:  2001-09-27       Impact factor: 17.173

6.  Caspase cleavage of mutant huntingtin precedes neurodegeneration in Huntington's disease.

Authors:  Cheryl L Wellington; Lisa M Ellerby; Claire-Anne Gutekunst; Danny Rogers; Simon Warby; Rona K Graham; Odell Loubser; Jeremy van Raamsdonk; Roshni Singaraja; Yu-Zhou Yang; Juliette Gafni; Dale Bredesen; Steven M Hersch; Blair R Leavitt; Sophie Roy; Donald W Nicholson; Michael R Hayden
Journal:  J Neurosci       Date:  2002-09-15       Impact factor: 6.167

7.  Polyglutamine-expanded ataxin-7 promotes non-cell-autonomous purkinje cell degeneration and displays proteolytic cleavage in ataxic transgenic mice.

Authors:  Gwenn A Garden; Randell T Libby; Ying-Hui Fu; Yoshito Kinoshita; Jing Huang; Daniel E Possin; Annette C Smith; Refugio A Martinez; Gabriel C Fine; Sara K Grote; Carol B Ware; David D Einum; Richard S Morrison; Louis J Ptacek; Bryce L Sopher; Albert R La Spada
Journal:  J Neurosci       Date:  2002-06-15       Impact factor: 6.167

8.  Proteomics of the eukaryotic transcription machinery: identification of proteins associated with components of yeast TFIID by multidimensional mass spectrometry.

Authors:  Steven L Sanders; Jennifer Jennings; Adrian Canutescu; Andrew J Link; P Anthony Weil
Journal:  Mol Cell Biol       Date:  2002-07       Impact factor: 4.272

9.  Genetic modulation of polyglutamine toxicity by protein conjugation pathways in Drosophila.

Authors:  H Y Edwin Chan; John M Warrick; Isabella Andriola; Diane Merry; Nancy M Bonini
Journal:  Hum Mol Genet       Date:  2002-11-01       Impact factor: 6.150

10.  Huntingtin forms toxic NH2-terminal fragment complexes that are promoted by the age-dependent decrease in proteasome activity.

Authors:  Hui Zhou; Fengli Cao; Zhishan Wang; Zhao-Xue Yu; Huu-Phuc Nguyen; Joy Evans; Shi-Hua Li; Xiao-Jiang Li
Journal:  J Cell Biol       Date:  2003-10-13       Impact factor: 10.539

View more
  24 in total

1.  SIRT1 modulates aggregation and toxicity through deacetylation of the androgen receptor in cell models of SBMA.

Authors:  Heather L Montie; Richard G Pestell; Diane E Merry
Journal:  J Neurosci       Date:  2011-11-30       Impact factor: 6.167

Review 2.  Autophagy gone awry in neurodegenerative diseases.

Authors:  Esther Wong; Ana Maria Cuervo
Journal:  Nat Neurosci       Date:  2010-07       Impact factor: 24.884

Review 3.  Repeat expansion disease: progress and puzzles in disease pathogenesis.

Authors:  Albert R La Spada; J Paul Taylor
Journal:  Nat Rev Genet       Date:  2010-04       Impact factor: 53.242

4.  Matrix metalloproteinases are modifiers of huntingtin proteolysis and toxicity in Huntington's disease.

Authors:  John P Miller; Jennifer Holcomb; Ismael Al-Ramahi; Maria de Haro; Juliette Gafni; Ningzhe Zhang; Eugene Kim; Mario Sanhueza; Cameron Torcassi; Seung Kwak; Juan Botas; Robert E Hughes; Lisa M Ellerby
Journal:  Neuron       Date:  2010-07-29       Impact factor: 17.173

5.  Differential degradation of full-length and cleaved ataxin-7 fragments in a novel stable inducible SCA7 model.

Authors:  Xin Yu; Abiodun Ajayi; Narasimha Rao Boga; Anna-Lena Ström
Journal:  J Mol Neurosci       Date:  2012-02-25       Impact factor: 3.444

Review 6.  PolyQ disease: misfiring of a developmental cell death program?

Authors:  Elyse S Blum; Andrew R Schwendeman; Shai Shaham
Journal:  Trends Cell Biol       Date:  2012-12-08       Impact factor: 20.808

7.  Reelin is a target of polyglutamine expanded ataxin-7 in human spinocerebellar ataxia type 7 (SCA7) astrocytes.

Authors:  Shaun D McCullough; Xiaojiang Xu; Sharon Y R Dent; Stefan Bekiranov; Robert G Roeder; Patrick A Grant
Journal:  Proc Natl Acad Sci U S A       Date:  2012-12-10       Impact factor: 11.205

Review 8.  Autophagy in polyglutamine disease: Imposing order on disorder or contributing to the chaos?

Authors:  Constanza J Cortes; Albert R La Spada
Journal:  Mol Cell Neurosci       Date:  2015-03-11       Impact factor: 4.314

9.  Proteolysis of Ambra1 during apoptosis has a role in the inhibition of the autophagic pro-survival response.

Authors:  V Pagliarini; E Wirawan; A Romagnoli; F Ciccosanti; G Lisi; S Lippens; F Cecconi; G M Fimia; P Vandenabeele; M Corazzari; M Piacentini
Journal:  Cell Death Differ       Date:  2012-03-23       Impact factor: 15.828

10.  Consensus paper: pathological mechanisms underlying neurodegeneration in spinocerebellar ataxias.

Authors:  A Matilla-Dueñas; T Ashizawa; A Brice; S Magri; K N McFarland; M Pandolfo; S M Pulst; O Riess; D C Rubinsztein; J Schmidt; T Schmidt; D R Scoles; G Stevanin; F Taroni; B R Underwood; I Sánchez
Journal:  Cerebellum       Date:  2014-04       Impact factor: 3.847

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.